Cargando…

Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan

INTRODUCTION: This post-marketing observational interim analysis evaluated the 12-month effectiveness and safety of omidenepag isopropyl (OMDI) ophthalmic solution in daily clinical settings. METHODS: This was a multicenter, large-scale, non-interventional, prospective, observational study conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakazawa, Toru, Takahashi, Kanji, Kuwayama, Yasuaki, Nomura, Akio, Shimada, Fumiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918093/ https://www.ncbi.nlm.nih.gov/pubmed/35072890 http://dx.doi.org/10.1007/s12325-021-02035-8

Ejemplares similares

Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension
por: Matsuo, Masato, et al.
Publicado: (2022)

Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
por: Shiratori, Naka, et al.
Publicado: (2021)

The clinical effectiveness of tafluprost on Japanese normal-tension glaucoma patients
por: Nomura, Akio, et al.
Publicado: (2018)

Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2020)

Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study
por: Panarelli, Joseph F., et al.
Publicado: (2023)

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
por: Olander, Kenneth W., et al.
Publicado: (2021)

Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
por: Miki, Atsuya, et al.
Publicado: (2022)

Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study
por: Nakakura, Shunsuke, et al.
Publicado: (2021)

Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

Cystoid macular edema associated with omidenepag isopropyl in a phakic eye with an implantable collamer lens: a case report
por: Bae, Byung-Jin, et al.
Publicado: (2023)

Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

One-Year Follow-Up Study of Changes in Prostaglandin-Associated Periorbital Syndrome After Switch From Conventional Prostaglandin F2alfa to Omidenepag Isopropyl
por: Oogi, Satomi, et al.
Publicado: (2020)

Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study
por: Tanihara, Hidenobu, et al.
Publicado: (2020)

Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study
por: Tanihara, Hidenobu, et al.
Publicado: (2019)

Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
por: Wirta, David L., et al.
Publicado: (2022)

Correction to: Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study
por: Tanihara, Hidenobu, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
por: Aihara, Makoto, et al.
Publicado: (2019)

Comparison of the Drug-Induced Efficacies between Omidenepag Isopropyl, an EP2 Agonist and PGF2α toward TGF-β2-Modulated Human Trabecular Meshwork (HTM) Cells
por: Suzuki, Soma, et al.
Publicado: (2022)

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
por: Saida, Takahiko, et al.
Publicado: (2017)

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
por: Yokoyama, Seiji, et al.
Publicado: (2021)

The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
por: Yabana, Takeshi, et al.
Publicado: (2019)

Classification of optic disc shape in glaucoma using machine learning based on quantified ocular parameters
por: Omodaka, Kazuko, et al.
Publicado: (2017)

Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12‐week interim analysis of post‐marketing surveillance in Japan
por: Hayashi, Nobukazu, et al.
Publicado: (2022)

Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan
por: Hongo, Haruyuki, et al.
Publicado: (2021)

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice
por: Esaki, Yoshihiko, et al.
Publicado: (2020)

Effect of Prostaglandin E2 Agonist Omidenepag on the Expression of Matrix Metalloproteinase in Trabecular Meshwork Cells
por: Kim, Jeong Yeub, et al.
Publicado: (2022)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Kato, Hideki, et al.
Publicado: (2018)

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Ito, Shuichi, et al.
Publicado: (2018)

Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan
por: Hiraishi, Itaru, et al.
Publicado: (2021)

Safety and Effectiveness of Molnupiravir (LAGEVRIO(®)) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
por: Kimata, Masahiro, et al.
Publicado: (2023)

Brimonidine in the treatment of glaucoma and ocular hypertension
por: Cantor, Louis B
Publicado: (2006)

Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice: interim data from post-marketing surveillance in Japan
por: Tanabe, Nobuhiro, et al.
Publicado: (2020)

Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells
por: Yamamoto, Yasuko, et al.
Publicado: (2020)

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023)

Ocular Biomechanics and Glaucoma
por: Brazuna, Rodrigo, et al.
Publicado: (2023)

Topical Medication Therapy for Glaucoma and Ocular Hypertension
por: Wang, Tao, et al.
Publicado: (2021)

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
por: Fung, Derrick S, et al.
Publicado: (2014)

Association Between Alcohol Consumption Patterns and Glaucoma in Japan
por: Sano, Kei, et al.
Publicado: (2023)

Interim Analysis of STREAMLINE(®) Surgical System Clinical Outcomes in Eyes with Glaucoma
por: Lazcano-Gomez, Gabriel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_adq6ma29q74jpig4hc98ipbb28